by Paper at NIH here.28 proteins, including ofc the Spike:The viral genome of the coronavirus encodes four structural proteins named spike (S), envelope (E), membrane (M), and nucleocapsid (N), 16 non-structural proteins (nsp1–16), and 8 accessory proteins. The S protein plays the most critical role in viral attachment, fusion, and entry into the target cell mRNA gets a mention but not much else... this is it:mRNA has been used as a template for endogenous expression of proteins selected as a vaccine candidate. An mRNA vaccine is a promising alternative because of its high potency, short production cycle, and low manufacturing cost. (Pardi et al., 2018; Yun et al., 2020). Currently, there is no mRNA vaccine in the market, so it will be challenging to pass the quality control and safety
Topics:
Mike Norman considers the following as important:
This could be interesting, too:
Robert Vienneau writes Austrian Capital Theory And Triple-Switching In The Corn-Tractor Model
Mike Norman writes The Accursed Tariffs — NeilW
Mike Norman writes IRS has agreed to share migrants’ tax information with ICE
Mike Norman writes Trump’s “Liberation Day”: Another PR Gag, or Global Reorientation Turning Point? — Simplicius
28 proteins, including ofc the Spike:
The viral genome of the coronavirus encodes four structural proteins named spike (S), envelope (E), membrane (M), and nucleocapsid (N), 16 non-structural proteins (nsp1–16), and 8 accessory proteins. The S protein plays the most critical role in viral attachment, fusion, and entry into the target cell
mRNA gets a mention but not much else... this is it:
mRNA has been used as a template for endogenous expression of proteins selected as a vaccine candidate. An mRNA vaccine is a promising alternative because of its high potency, short production cycle, and low manufacturing cost. (Pardi et al., 2018; Yun et al., 2020). Currently, there is no mRNA vaccine in the market, so it will be challenging to pass the quality control and safety evaluation. Currently, mRNA-1273, a potential vaccine against SARS-CoV-2 based on encoding for a prefusion stabilized form of the S protein, has been selected for evaluation by Moderna in collaboration with investigators at the NIAID Vaccine Research Center (VRC). This vaccine is currently the focus of a Phase 1 clinical trial (NCT04283461). Several other companies are also developing mRNA vaccines against SARS-CoV-2 (Table 5 ).
mRNA vaccines are now current the only type of vaccines being administered in the US...